Compare Bristol-Myers Squibb Co (BMY) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Vital Farms Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Vital Farms Inc trades at $11.45 (market cap $496.50M). The key difference: Bristol-Myers Squibb Co is far larger — about 261.7× Vital Farms Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| BMY | VITL | |
|---|---|---|
Market Cap | $129.94B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $65.89 | $52.41 |
52-Week Low | $42.60 | $8.28 |
Enterprise Value | $163.92B | $583.51M |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
VITL trades at $11.48, up 1.95% on the day, but faces significant technical headwinds with a bearish moving average signal. The company reported mixed Q2 2026 results, beating revenue estimates but posting a $0.47 per share loss amid industry oversupply challenges. Recent $125 million term loan financing provides liquidity support during this transitional period.
While analyst consensus remains positive with a $13.00 price target, near-term risks include margin compression from elevated costs and competitive pricing pressures. The stock's attractive P/S ratio of 0.67 offers value potential if the company can navigate current industry headwinds and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
